Three Months Ended March 31,

Common Stock

Other
Paid-In
Capital

Retained
Earnings

Accumulated
Other
Comprehensive
Loss

Treasury Stock

Non-
controlling
Interests

Total

($ and shares in millions except per share amounts)

Shares

Par Value

Shares

Cost

Balance at January 1, 2022

3,577

$

1,788

$

44,238

$

53,696

$

(4,429)

1,049

$

(57,109)

$

73

$

38,257

Net income attributable to Merck & Co., Inc.

—

4,310

—

4,310

Other comprehensive income, net of taxes

—

60

—

60

Cash dividends declared on common stock ($0.69 per share)

—

(1,754)

—

(1,754)

Share-based compensation plans and other

—

37

—

46

—

83

Net loss attributable to noncontrolling interests

—

(3)

Balance at March 31, 2022

3,577

$

1,788

$

44,275

$

56,252

$

(4,369)

1,049

$

(57,063)

$

70

$

40,953

Balance at January 1, 2023

3,577

$

1,788

$

44,379

$

61,081

$

(4,768)

1,039

$

(56,489)

$

67

$

46,058

Net income attributable to Merck & Co., Inc.

—

2,821

—

2,821

Other comprehensive loss, net of taxes

—

(115)

—

(115)

Cash dividends declared on common stock ($0.73 per share)

—

(1,863)

—

(1,863)

Treasury stock shares purchased

—

1

(149)

—

(149)

Share-based compensation plans and other

—

88

—

61

—

149

Net income attributable to noncontrolling interests

—

4

Balance at March 31, 2023

3,577

$

1,788

$

44,467

$

62,039

$

(4,883)

1,040

$

(56,577)

$

71

$

46,905